In our study, we show that transcriptional levels of SLC2A1, SLC2A5 are upregulated and those of SLC2A3, SLC2A6, SLC2A9, SLC2A14 are downregulated in LUAD patients, supporting the role of SLC2A1, SLC2A5 as oncogenes and SLC2A3, SLC2A6, SLC2A9, SLC2A14 as tumor suppressor genes. This evidence concerns the gene SLC2A9 and neoplasm.